A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

Clinical trial NCT05032157 · COMPLETED

Trial details

NCT number: NCT05032157
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Spontaneous Urticaria

Start date: 2021-12-01
Primary completion: 2023-12-18
Enrollment: 455

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.